Cho R. Hong

85 Park Rd
Grafton, AUK 1023, New Zealand

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Journal: Journal of medicinal chemistry
Published: July 15, 2024

Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.

Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.

Journal: Molecules (Basel, Switzerland)
Published: May 05, 2023

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Journal: JCI insight
Published: February 22, 2023

Spin Trapping Hydroxyl and Aryl Radicals of One-Electron Reduced Anticancer Benzotriazine 1,4-Dioxides.

Spin Trapping Hydroxyl and Aryl Radicals of One-Electron Reduced Anticancer Benzotriazine 1,4-Dioxides.

Journal: Molecules (Basel, Switzerland)
Published: December 15, 2021

Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.

Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 27, 2021

Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Journal: Cancer chemotherapy and pharmacology
Published: April 15, 2021

Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Journal: Cancer biology & therapy
Published: May 28, 2019

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Journal: Molecular pharmacology
Published: November 11, 2018

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.

Journal: Neoplasia (New York, N.Y.)
Published: September 06, 2018

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.

Journal: Frontiers in pharmacology
Published: June 01, 2018

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Journal: Biochemical pharmacology
Published: May 29, 2018

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Journal: JCI insight
Published: May 14, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026